You are here

The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK101221-01
Agency Tracking Number: R41DK101221
Amount: $223,390.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDDK
Solicitation Number: PA13-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2929 7TH ST STE 100
BERKELEY, CA 94710
United States
DUNS: 964173801
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ALBERT CANDIA
 (415) 725-7611
 acandia@dynavax.com
Business Contact
 ROBERT COFFMAN
Phone: (510) 665-7224
Email: rcoffman@dynavax.com
Research Institution
 YALE UNIV
 
YALE UNIVERSITY 47 COLLEGE STREET, STE 203 PO BOX 208047
NEW HAVEN, CT 06520-8047
United States

 () -
 Nonprofit college or university
Abstract

DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the TLR7/9 oligonucleotide-based antagonist IRS954, developed by Dynavax, blocks the development of HF when given prophylactically. This project attempts to confirm and expand the preclinical feasibility data and potential for IRS954 to be a novel therapy for HF with the following Specific Aims: Aim 1: Evaluate the pharmacokinetics and tissue distribution of IRS954 innormal and HF animals by clinically relevant dosing routes of administration. a. Compare levels of IRS954 in the liver of normal animals dosed intraperitoneally with those of animals receiving more clinically relevant subcutaneous and intravenous dosing.b. Compare the levels of IRS954 in the liver of normal and HF mice with the optimal dosing conditions from part a. Aim 2: Establish the activity of IRS954 in blocking progression and in promoting regression of HF. a. Test the ability of IRS954 to inhibitearly and late fibrotic phases using dosing conditions determined from Aim 1. b. Test the ability of IRS954 to promote fibrotic regression. Results from the above aims will provide additional supporting, preclinical evidence of the feasibility and utility of IRS954 as a potential therapeutic to limit progression and reverse HF. PUBLIC HEALTH RELEVANCE Public Health Relevance: The goal of this project is to improve the management of fibrotic liver disease by developing novel anti-fibrotic therapies thatdisrupt multiple pathological processes through targeting the TLR7 and TLR9 pathway. PUBLIC HEALTH RELEVANCE: When the liver is repeatedly injured by alcohol abuse or hepatitis viral infection, hepatic fibrosis is part of the response to these injuries, and if left untreated it can lead to irreversible liver damage (cirrhosis) and further serious complications such as hypertension, liver failure, and liver cancer. Currently, liver transplantation is the only definitive therapy for cirrhosis and it is not available to most patients. This project will determne whether a novel molecule has the potential to be a therapeutic to stop the progression or reverse hepatic fibrosis following liver injury.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government